ArticleCancers2021
Comparison of Oncologic Outcomes between Carbon Ion Radiotherapy and Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Biological effects of cancer stem cells irradiated by charged particle: a systematic review of in vitro studies.Journal of cancer research and clinical oncology · 2023Pooled it
- Carbon ion radiotherapy and radiation-induced lung injury: clinical evidence, mechanistic insights, and future directions.Frontiers in oncology · 2026Review
- AI-based prediction of recurrence after carbon ion radiotherapy for early stage non-small cell lung cancer.PloS one · 2026Article
- Stereotactic body radiotherapy for early‑stage non‑small cell lung cancer: Comprehensive analysis of outcomes and recurrence from a single‑center experience.Oncology letters · 2025Article
- Investigation of factors related to treatment planning of x-ray SBRT and scanning carbon-ion radiation therapy for early-stage lung cancer patients.Journal of applied clinical medical physics · 2025Article
- Clinical indications and future directions of carbon-ion radiotherapy: a narrative review.Ewha medical journal · 2024Review
- Hypoxia predicts favorable response to carbon ion radiotherapy in non-small cell lung cancer (NSCLC) defined byQuantitative imaging in medicine and surgery · 2024Article
- Molecular mechanism of radiation tolerance in lung adenocarcinoma cells using single-cell RNA sequencing.Journal of cellular and molecular medicine · 2024Article
- Radiation-induced organizing pneumonia caused by carbon-ion radiotherapy for lung cancer.Radiology case reports · 2024Article
- Analysis of the relationship between LET, γH2AX foci volume and cell killing effect of carbon ions using high-resolution imaging technology.Journal of radiation research · 2023Article
- Value of carbon-ion radiotherapy for early stage non-small cell lung cancer.Clinical and translational radiation oncology · 2022Review
- CircNEIL3 mediates pyroptosis to influence lung adenocarcinoma radiotherapy by upregulating PIF1 through miR-1184 inhibition.Cell death & disease · 2022Article
- Cost-effectiveness of carbon-ion radiotherapy versus stereotactic body radiotherapy for non-small-cell lung cancer.Cancer science · 2022Article
- A Promising Treatment Strategy for Lung Cancer: A Combination of Radiotherapy and Immunotherapy.Cancers · 2021Review
- Article
- Silencing of the lncRNA H19 enhances sensitivity to X-ray and carbon-ions through the miR-130a-3p /WNK3 signaling axis in NSCLC cells.Cancer cell international · 2021Article
- Who Will Benefit from Charged-Particle Therapy?Cancer research and treatment · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is a leading cause of cancer-related deaths worldwide. Radiotherapy is an essential treatment modality for inoperable non-small cell lung cancer (NSCLC). Stereotactic body radiotherapy (SBRT) is the standard treatment for early-stage NSCLC because of its favorable local control (LC) compared to conventional radiotherapy. Carbon ion radiotherapy (CIRT) is a kind of external beam radiotherapy characterized by a steeper dose distribution and higher biological effectiveness. Several prospective studies have shown favorable outcomes. However, there is no direct comparison study between CIRT and SBRT to determine their benefits in the management of early-stage NSCLC. Thus, we conducted a retrospective, single-institutional, and contemporaneous comparison study, including propensity score-adjusted analyses, to clarify the differences in oncologic outcomes. The 3-year overall survival (OS) was 80.1% in CIRT and 71.6% in SBRT (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.